Sarepta Therapeutics, Inc.
SRPT
$18.10
-$0.32-1.74%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -34.34% | -1.89% | -32.73% | -14.52% | 68.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.34% | -1.89% | -32.73% | -14.52% | 68.38% |
| Cost of Revenue | -5.92% | -71.16% | 117.92% | 16.92% | -25.15% |
| Gross Profit | -45.10% | 381.71% | -186.19% | -80.34% | 219.59% |
| SG&A Expenses | -21.97% | -18.47% | -21.71% | -28.32% | -0.65% |
| Depreciation & Amortization | 7.50% | 14.98% | 12.65% | 12.46% | 10.98% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.58% | -64.37% | 71.73% | 3.88% | 36.27% |
| Operating Income | -54.76% | 219.32% | -353.64% | -383.29% | 16,587.45% |
| Income Before Tax | -101.14% | 189.48% | -262.04% | -670.63% | 1,031.60% |
| Income Tax Expenses | 107.26% | -80.91% | -64.15% | -3,670.13% | -707.76% |
| Earnings from Continuing Operations | -102.48% | 173.96% | -277.84% | -635.38% | 2,947.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.48% | 173.96% | -277.84% | -635.38% | 2,947.86% |
| EBIT | -54.76% | 219.32% | -353.64% | -383.29% | 16,587.45% |
| EBITDA | -50.40% | 227.07% | -335.18% | -238.83% | 1,476.67% |
| EPS Basic | -102.31% | 168.59% | -263.39% | -609.42% | 2,841.43% |
| Normalized Basic EPS | -70.31% | 208.21% | -335.38% | -347.15% | 4,068.18% |
| EPS Diluted | -102.65% | 162.61% | -267.36% | -631.44% | 2,662.81% |
| Normalized Diluted EPS | -67.70% | 193.18% | -365.21% | -360.22% | 3,913.69% |
| Average Basic Shares Outstanding | 7.58% | 7.83% | 8.84% | 5.08% | 3.58% |
| Average Diluted Shares Outstanding | -1.12% | 25.22% | -3.39% | -0.21% | 7.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |